Access the Next-Generation of Cancer Diagnostics

One of the major challenges in diagnosing hematological and solid tumor cancers is the high degree of tumor heterogeneity. Mutations that have critical clinical implications may only be present in very low levels, making detection of these mutations difficult. Detection of such mutations is especially important in hematological and solid tumor malignancies, where tumors show a great deal of heterogeneity and accurate prognosis is essential to identifying patient with more aggressive disease. Next-generation sequencing (NGS) helps respond to these challenges by providing a comprehensive view of the tumor’s genomic profile. Importantly, NGS can detect multiple mutations present at very low levels within the tumor.


Targeted NGS Panels for B-Cell Lymphomas
CGI’s Lymphoma NGS panels provide powerful and clinically validated tools for the molecular characterization of lymphomas. The targeted NGS panels in the table below report on clinically actionable gene mutations present in the most common types of B-cell lymphomas, representing nearly 300,000 patients living with the disease in the USA. These Focus::NGS™ panels for lymphoma have been used to power several clinical trials with biopharmaceutical companies and are also available for clinical diagnostic work up, management and therapy selection in lymphoma patients. The Lymphoma Extended™ NGS panel is also available to detect mutations in 220 selected genes under investigation in Lymphomas


Lymphoma NGS Panel   # of Genes   Indication
Focus::CLL 25 Chronic Lymphocytic Leukemia
Focus::MCL 34 Mantle Cell Lymphoma
Focus::DLBCL&FL 45 Diffuse Large B-Cell Lymphoma & Follicular Lymphoma
Focus::Lymphoma 50 Other Subtypes of Lymphoma
Lymphoma Extended 220 Full Lymphoma Research Panel